Table 3.
BRAF and TERT promoter mutations and clinicopathologic features in patients with PTC.
| Total PTC | PTC > 1 cm | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variables | No Mutation |
BRAF V600E Mutation Only |
p- Value |
pTERT Mutation Only |
p- Value |
BRAF+ pTERT Mutations |
p- Value |
No Mutation |
BRAF V600E Mutation Only |
p- Value |
pTERT Mutation Only |
p- Value |
BRAF+ pTERT Mutations |
p- Value |
| No. of cases | 1234 (15.8) | 6476 (83.1) | 17 (0.2) | 70 (0.9) | 465 (21.1) | 1669 (75.7) | 16 (0.7) | 55 (2.5) | ||||||
| Age (year) | 42.52 ± 12.56 |
43.14 ± 11.93 | 0.113 | 58.18 ± 14.22 |
<0.001 | 63.16 ± 11.52 | <0.001 | 39.67 ± 12.71 |
42.29 ± 12.97 | <0.001 | 58.75 ± 14.48 |
<0.001 | 64.29 ± 11.79 | <0.001 |
| ≥55 | 240 (19.4) | 1241 (19.2) | 0.815 | 9 (52.9) | 0.001 | 57 (81.4) | <0.001 | 64 (13.8) | 319 (19.1) | 0.008 | 9 (56.3) | <0.001 | 45 (81.8) | <0.001 |
| Sex, Male | 228 (18.5) | 1537 (23.7) | <0.001 | 4 (23.5) | 0.573 | 35 (50.0) | <0.001 | 108 (23.2) | 483 (28.9) | 0.015 | 4 (25.0) | 0.772 | 30 (54.5) | <0.001 |
| Tumor size (cm) | 1.09 ± 0.95 | 0.86 ± 0.59 | <0.001 | 2.92 ± 1.98 | 0.002 | 1.72 ± 0.93 | <0.001 | 1.95 ± 1.05 | 1.62 ± 0.68 | <0.001 | 3.06 ± 1.95 | 0.039 | 2.01 ± 0.83 | 0.666 |
| >1.0 | 465 (37.7) | 1669 (25.8) | <0.001 | 16 (94.1) | <0.001 | 55 (78.6) | <0.001 | - | - | - | - | - | ||
| Multiplicity | 384 (31.1) | 2153 (33.2) | 0.145 | 13 (76.5) | <0.001 | 32 (45.7) | 0.011 | 179 (38.5) | 698 (41.8) | 0.197 | 12 (75.0) | 0.007 | 27 (49.1) | 0.129 |
| Extrathyroidal extension | 95 (7.7) | 597 (9.2) | 0.087 | 6 (35.3) | <0.001 | 37 (52.9) | <0.001 | 80 (17.2) | 435 (26.1) | <0.001 | 6 (37.5) | 0.037 | 34 (61.8) | <0.001 |
| Histology | ||||||||||||||
| Classic | 945 (76.6) | 6164 (95.2) | <0.001 | 7 (41.2) | 0.043 | 66 (94.3) | 0.018 | 300 (64.5) | 1575 (94.4) | <0.001 | 7 (43.8) | 0.485 | 51 (92.7) | 0.003 |
| Follicular variant | 223 (18.1) | 173 (2.7) | 9 (52.9) | 0 (0.0) | 124 (26.7) | 55 (3.3) | 8 (50.0) | 0 (0.0) | ||||||
| Tall-cell variant | 1 (0.1) | 75 (1.2) | 0 (0.0) | 3 (4.3) | 0 (0.0) | 19 (1.1) | 0 (0.0) | 3 (5.5) | ||||||
| Others | 65 (5.3) | 64 (1.0) | <0.001 | 1 (5.9) | 0.001 | 1 (1.4) | <0.001 | 41 (8.8) | 20 (1.2) | 1 (6.3) | 1 (1.8) | |||
| Histology, Variants | 289 (23.4) | 312 (4.8) | 10 (58.8) | 4 (5.7) | 165 (35.5) | 94 (5.6) | <0.001 | 9 (56.3) | 0.089 | 4 (7.3) | <0.001 | |||
| Perinodal infiltration | 138 (11.2) | 563 (8.7) | 0.005 | 2 (11.8) | 1.000 | 28 (40.0) | <0.001 | 100 (21.5) | 312 (18.7) | 0.174 | 2 (12.5) | 0.541 | 24 (43.6) | <0.001 |
| T stage | ||||||||||||||
| T1 | 1028 (83.3) | 5732 (88.5) | <0.001 | 6 (35.3) | <0.001 | 28 (40.0) | <0.001 | 274 (58.9) | 1087 (65.1) | 0.860 | 5 (31.3) | 0.008 | 16 (29.1) | <0.001 |
| T2 | 93 (7.5) | 141 (2.2) | 3 (17.6) | 5 (7.1) | 93 (20.0) | 141 (8.4) | 3 (18.8) | 5 (9.1) | ||||||
| T3 | 82 (6.6) | 419 (6.5) | 6 (35.3) | 21 (30.0) | 72 (15.5) | 318 (19.1) | 6 (37.5) | 21 (38.2) | ||||||
| T4 | 31 (2.5) | 184 (2.8) | 2 (11.8) | 16 (22.9) | 26 (5.6) | 123 (7.4) | 2 (12.5) | 13 (23.6) | ||||||
| T stage, T3–T4 | 113 (9.2) | 603 (9.3) | 0.864 | 8 (47.1) | <0.001 | 37 (52.9) | <0.001 | 98 (21.1) | 441 (26.4) | 0.019 | 8 (50.0) | 0.006 | 34 (61.8) | <0.001 |
| N stage | ||||||||||||||
| N0 | 726 (58.8) | 3549 (54.8) | <0.001 | 10 (58.8) | 0.416 | 26 (37.1) | 0.001 | 201 (43.2) | 546 (32.7) | 0.687 | 10 (62.5) | 0.421 | 18 (32.7) | 0.385 |
| N1a | 326 (26.4) | 2361 (36.5) | 2 (11.8) | 27 (38.6) | 128 (27.5) | 784 (47.0) | 1 (6.3) | 21 (38.2) | ||||||
| N1b | 182 (14.7) | 566 (8.7) | 5 (29.4) | 17 (24.3) | 136 (29.2) | 339 (20.3) | 5 (31.3) | 16 (29.1) | ||||||
| N stage, N1 | 508 (41.2) | 2927 (45.2) | 0.009 | 7 (41.2) | 0.999 | 44 (62.9) | <0.001 | 264 (56.8) | 1123 (67.3) | <0.001 | 6 (37.5) | 0.127 | 37 (67.3) | 0.136 |
| M stage | ||||||||||||||
| M0 | 1225 (99.3) | 6470 (99.9) | <0.001 | 13 (76.5) | <0.001 | 66 (94.3) | 0.004 | 456 (98.1) | 1666 (99.8) | <0.001 | 12 (75.0) | <0.001 | 52 (94.5) | 0.124 |
| M1 | 9 (0.7) | 6 (0.1) | 4 (23.5) | 4 (5.7) | 9 (1.9) | 3 (0.2) | 4 (25.0) | 3 (5.5) | ||||||
| TNM stage | ||||||||||||||
| I | 1059 (85.8) | 5476 (84.6) | 0.435 | 6 (35.3) | <0.001 | 20 (28.6) | <0.001 | 383 (82.4) | 1278 (76.6) | 0.005 | 6 (37.5) | <0.001 | 13 (23.6) | <0.001 |
| II | 170 (13.8) | 954 (14.7) | 5 (29.4) | 35 (50.0) | 79 (17.0) | 360 (21.6) | 4 (25.0) | 30 (54.5) | ||||||
| III | 4 (0.3) | 42 (0.6) | 2 (11.8) | 11 (15.7) | 2 (0.4) | 28 (1.7) | 2 (12.5) | 9 (16.4) | ||||||
| IV | 1 (0.1) | 4 (0.1) | 4 (23.5) | 4 (5.7) | 1 (0.2) | 3 (0.2) | 4 (25.0) | 3 (5.5) | ||||||
| TNM stage, III–IV |
5 (0.4) | 46 (0.7) | 0.226 | 6 (35.3) | <0.001 | 15 (21.4) | <0.001 | 3 (0.6) | 31 (1.9) | 0.091 | 6 (37.5) | <0.001 | 12 (21.8) | <0.001 |
| RAI therapy |
250 (20.3) | 1182 (18.3) | 0.097 | 12 (70.6) | <0.001 | 42 (60.0) | <0.001 | 167 (35.9) | 657 (39.4) | 0.176 | 12 (75.0) | 0.003 | 37 (67.3) | <0.001 |
Values are expressed as the mean ± standard deviation or as numbers (%). PTC, papillary thyroid cancer; pTERT, TERT promoter; RAI, radioactive iodine.